PaulBChapmanMD

Attending Physician, Memorial Sloan Kettering Cancer Center. Professor of Medicine, Cornell University-Weill Medical College

Request Appointment

Overview of Dr. Chapman

Dr. Paul Chapman is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian Brooklyn Methodist Hospital, Memorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and allied Diseases, Memorial Hospital for Cancer and allied Diseases, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Weill Cornell Medicine and has been in practice 36 years. Dr. Chapman accepts several types of health insurance, listed below. He is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
1275 York Ave
New York, NY 10065
Book by Phone+1(520) 487-4409

Education & Training

Memorial Sloan Kettering Cancer CenterImmunology, 1984 - 1988
University of ChicagoResidency, Internal Medicine, 1981 - 1984
Weill Cornell MedicineClass of 1981

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1988 - 2026
NJ State Medical License 2020 - 2025
IL State Medical License 1981 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 1997 Nov 01
Completed
Phase 2
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma Start of enrollment: 1998 May 01
Completed
Phase 2
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01
Withdrawn
Phase 2
Tanespimycin in Treating Patients With Stage III-IV Melanoma Start of enrollment: 2004 Jun 01
Terminated
Phase 2
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection Start of enrollment: 2005 Sep 01
Completed
Phase 2
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma Start of enrollment: 2005 Jan 01
Completed
Phase 2
Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma Start of enrollment: 2007 Dec 01
Completed
Not Applicable
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma Start of enrollment: 2009 Apr 01
Completed
Phase 2
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation Start of enrollment: 2011 Nov 01
Terminated
Phase 2
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation Start of enrollment: 2012 Sep 01
Completed
Phase 2
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation Start of enrollment: 2013 Jul 01
Completed
Phase 2
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma Start of enrollment: 2014 Apr 09
Completed
Phase 2
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma Start of enrollment: 2017 May 16
Completed
Phase 1
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery Start of enrollment: 2019 Feb 14
Completed
Join now to see all

Publications & Presentations

PubMed

29 citations
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
Katherine Lee Chuy, Evangelos Oikonomou, Michael A. Postow, Margaret K. Callahan, Paul B. Chapman
The Oncologist. 2019-05-01
1316 citations
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma
Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N. Ibrahim
Nature. 2010-09-30
109 citations
Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
Federica Catalanotti, David B. Solit, Melissa Pulitzer, Michael F. Berger, Sasinya N. Scott
Clinical Cancer Research. 2013-04-15

Press Mentions

Time's up for Anti-PD-1/L1 plus Targeted Therapy in BRAF MelanomaJanuary 26th, 2022
Merck’s Proposed Less Frequent Keytruda Dosing May Allow for Minor Uptake BoostNovember 19th, 2019
Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma PatientsJune 19th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Health Alliance PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Wellmark Alliance Select
Please verify your coverage with the provider's office directly when scheduling an appointment